Literature DB >> 28431598

Apraclonidine in the treatment of ptosis.

Subhashie Wijemanne1, Dhanya Vijayakumar1, Joseph Jankovic2.   

Abstract

Transient ptosis is a known complication of botulinum toxin (BoNT) injection due to inadvertent migration of toxin into the levator palpebrae superioris muscle. Currently there is no treatment available for BoNT induced ptosis. Apraclonidine hydrochloride is a topical ophthalmic solution with selective alpha-2 and weak alpha-1 receptor agonist activity that has the ability to elevate the eye lid. Apraclonidine has been used as a diagnostic test in Horner's syndrome. We evaluated the effects apraclonidine in a cohort of BoNT induced ptosis and a patient with Horner syndrome. Each patient was administered 2 drops of apraclonidine 0.5% solution to the eye with the ptosis and was re-examined 20-30min later. All 6 patients showed improvement in ptosis. There was also improvement in ptosis in a patient with Horner's syndrome. Apraclonidine is not only useful as a diagnostic test in Horner's syndrome, but may be an effective and safe treatment for BoNT-induced ptosis.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apraclonidine; Botulinum toxin; Horner's syndrome; Ptosis

Mesh:

Substances:

Year:  2017        PMID: 28431598     DOI: 10.1016/j.jns.2017.03.025

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  5 in total

1.  Comment on: A trial of a mechanical device for the treatment of blepharospasm.

Authors:  Jonathan A Go; Ashley N Anderson; Ashwini Kini; Bayan Al Othman; Andrew G Lee
Journal:  Eye (Lond)       Date:  2019-10-04       Impact factor: 3.775

2.  Putting the Pieces Back Together: Optimizing Function and Appearance after Orbital Surgery.

Authors:  Kimberly Cockerham; Jacquelyn Laplant
Journal:  J Neurol Surg B Skull Base       Date:  2021-02-22

Review 3.  A review of acquired blepharoptosis: prevalence, diagnosis, and current treatment options.

Authors:  Jason Bacharach; Wendy W Lee; Andrew R Harrison; Thomas F Freddo
Journal:  Eye (Lond)       Date:  2021-04-29       Impact factor: 3.775

4.  Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials.

Authors:  David L Wirta; Michael S Korenfeld; Shane Foster; Robert Smyth-Medina; Jason Bacharach; Shane R Kannarr; Mark J Jaros; Charles B Slonim
Journal:  Clin Ophthalmol       Date:  2021-10-08

5.  Eyelid ptosis following botulinum toxin injection treated with briminodine 0.33% topical gel.

Authors:  Ghadah F Alotaibi; Sara F Alsukait; Hanan H Alsalman; Mohammed G Turkmani
Journal:  JAAD Case Rep       Date:  2022-01-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.